Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas

Molecular and Cellular Endocrinology

Volumn 286, Issue 1-2, 2008, Pages 206-213

  Saveanu, A ^a,b,c   Jaquet, P ^a,b   Brue, T ^a,b   Barlier, A ^a,b,c  

^a Le Centre de Recherche de Neurobiologie Neurophysiologie de Marseille   (France)

^b TIMONE HOSPITAL   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

Author keywords

D2DR; Dopamine; Dopastatin; Heterodimerization; Pituitary adenomas; Somatostatin; sst2; sst5

Indexed keywords

ANGIOPEPTIN; BIM 23 A 760; BIM 23 A 761; BIM 23 A 779; BIM 23244; BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPASTATIN; GROWTH HORMONE; OCTREOTIDE; PASIREOTIDE; QUINAGOLIDE; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5;

ARTICLE; BINDING AFFINITY; CELL CULTURE; CELL DIFFERENTIATION; COMBINATION CHEMOTHERAPY; DRUG BINDING; DRUG HALF LIFE; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION;

EID: 43749089979     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2007.12.008     Document Type: Article

References (90)

1. S. AbdAlla H. Lother A. el Massiery U. Quitterer Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness Nat. Med. 7 2001 1003 1009
2. M. Andersen P. Bjerre H.D. Schroder A. Edal P.F. Hoilund-Carlsen P.H. Pedersen C. Hagen In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas Clin. Endocrinol. (Oxford) 54 2001 23 30
3. D. Armstrong P.G. Strange Dopamine D2 receptor dimer formation: evidence from ligand binding J. Biol. Chem. 276 2001 22621 22629
4. S.L. Asa S. Ezzat The cytogenesis and pathogenesis of pituitary adenomas Endocr. Rev. 19 1998 798 827
5. A. Baragli H. Alturaihi H.L. Watt A. Abdallah U. Kumar Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis Cell Signal 19 2007 2304 2316
6. A. Barlier I. Pellegrini-Bouiller L. Caccavelli G. Gunz I. Morange-Ramos P. Jaquet A. Enjalbert Abnormal transduction mechanisms in pituitary adenomas Horm. Res. 47 1997 227 234
7. A. Barlier I. Pellegrini-Bouiller G. Gunz A.J. Zamora P. Jaquet A. Enjalbert Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity J. Clin. Endocrinol. Metab. 84 1999 2759 2765
8. D.L. Batista X. Zhang R. Gejman P.J. Ansell Y. Zhou S.A. Johnson B. Swearingen E.T. Hedley-Whyte C.A. Stratakis A. Klibanski The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas J. Clin. Endocrinol. Metab. 91 2006 4482 4488
9. N. Ben-Jonathan R. Hnasko Dopamine as a prolactin (PRL) inhibitor Endocr. Rev. 22 2001 724 763
10. R.G. Bhushan S.K. Sharma Z. Xie D.J. Daniels P.S. Portoghese A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers J. Med. Chem. 47 2004 2969 2972
11. C.B. Brink B.H. Harvey J. Bodenstein D.P. Venter D.W. Oliver Recent advances in drug action and therapeutics: relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology Br. J. Clin. Pharmacol. 57 2004 373 387
12. S. Bulenger S. Marullo M. Bouvier Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation Trends Pharmacol. Sci. 26 2005 131 137
13. L. Caccavelli F. Feron I. Morange E. Rouer R. Benarous D. Dewailly P. Jaquet C. Kordon A. Enjalbert Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas Neuroendocrinology 60 1994 314 322
14. L. Caccavelli I. Morange-Ramos C. Kordon P. Jaquet A. Enjalbert Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas J. Neuroendocrinol. 8 1996 737 746
15. M. Canals D. Marcellino F. Fanelli F. Ciruela P. de Benedetti S.R. Goldberg K. Neve K. Fuxe L.F. Agnati A.S. Woods S. Ferre C. Lluis M. Bouvier R. Franco Adenosine A2A-dopamine D2 receptor–receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer J. Biol. Chem. 278 2003 46741 46749
16. P. Caron S. Arlot C. Bauters P. Chanson J.M. Kuhn M. Pugeat R. Marechaud C. Teutsch E. Vidal P. Sassano Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas J. Clin. Endocrinol. Metab. 86 2001 2849 2853
17. C. Casnici D. Lattuada K. Crotta C. Mastrotto P. Franco M.D. Culler O. Marelli Effects of chimeric somatostatin–dopamine molecules on human peripheral blood lymphocytes activation J. Neuroimmunol. 179 2006 9 17
18. P. Chanson S. Brochier Non-functioning pituitary adenomas J. Endocrinol. Invest. 28 2005 93 99
19. A. Colao A. Di Sarno E. Guerra M. De Leo A. Mentone G. Lombardi Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women Nat. Clin. Pract. Endocrinol. Metab. 2 2006 200 210
20. A. Colao M. Filippella R. Pivonello C. Di Somma A. Faggiano G. Lombardi Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours Eur. J. Endocrinol. 156 2007 S57 S63
21. R. Cozzi R. Attanasio S. Lodrini G. Lasio Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status Clin. Endocrinol. (Oxford) 61 2004 209 215
22. M.D. Culler Dopamine and somatostatine chimeras 9th European Congress of Endocrinology pp. Ipsen Satellite Symposium, Budapest 2007
23. D. Ferone M. Arvigo C. Semino P. Jaquet A. Saveanu J.E. Taylor J.P. Moreau M.D. Culler M. Albertelli F. Minuto A. Barreca Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin–dopamine molecules on cell proliferation Am. J. Physiol. Endocrinol. Metab. 289 2005 E1044 E1050
24. T. Florio F. Barbieri R. Spaziante G. Zona L.J. Hofland P.M. van Koetsveld R.A. Feelders G.K. Stalla M. Theodoropoulou M.D. Culler J.P. Moreau A. Saveanu G. Gunz P. Jaquet Dopamine/somatostatin chimeric molecules inhibit proliferation of human clinically nonfunctioning adenoma cells in vitro: a multicenter study 12th Meeting of the European NeuroEndocrine Association Athens 2006 30 (S9.45)
25. P.U. Freda Somatostatin analogs in acromegaly J. Clin. Endocrinol. Metab. 87 2002 3013 3018
26. A. Fusco G. Gunz P. Jaquet M.D. Culler A. Barlier A. Saveanu Somatostatinergic ligands in dopamine sensitive or resistant prolactinomas The Endocrine Society's 89th Annual Meeting Toronto 2007 p. 298 (P1-555)
27. S.R. George B.F. O’Dowd S.P. Lee G-protein-coupled receptor oligomerization and its potential for drug discovery Nat. Rev. Drug Discov. 1 2002 808 820
28. M. Grant R.C. Patel U. Kumar The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors J. Biol. Chem. 279 2004 38636 38643
29. A. Gruszka J. Kunert-Radek A. Radek H. Pisarek J. Taylor J.Z. Dong M.D. Culler M. Pawlikowski The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the “clinically non-functioning” pituitary adenomas in vitro Life Sci. 78 2006 689 693
30. R. Guillemin Hypothalamic hormones a.k.a. hypothalamic releasing factors J. Endocrinol. 184 2005 11 28
31. Y. Hakak D. Shrestha M.C. Goegel D.P. Behan D.T. Chalmers Global analysis of G-protein-coupled receptor signaling in human tissues FEBS Lett. 550 2003 11 17
32. L.J. Hofland S.W. Lamberts P.M. van Hagen J.C. Reubi J. Schaeffer M. Waaijers P.M. van Koetsveld A. Srinivasan E.P. Krenning W.A. Breeman Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs J. Nucl. Med. 44 2003 1315 1321
33. L.J. Hofland J. van der Hoek P.M. van Koetsveld W.W. de Herder M. Waaijers D. Sprij-Mooij C. Bruns G. Weckbecker R. Feelders A.J. van der Lely A. Beckers S.W. Lamberts The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro J. Clin. Endocrinol. Metab. 89 2004 1577 1585
34. L.J. Hofland J. van der Hoek R. Feelders M.O. van Aken P.M. van Koetsveld M. Waaijers D. Sprij-Mooij C. Bruns G. Weckbecker W.W. de Herder A. Beckers S.W. Lamberts The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5 Eur. J. Endocrinol. 152 2005 645 654
35. P. Jaquet L. Ouafik A. Saveanu G. Gunz F. Fina H. Dufour M.D. Culler J.P. Moreau A. Enjalbert Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas J. Clin. Endocrinol. Metab. 84 1999 3268 3276
36. P. Jaquet A. Saveanu G. Gunz F. Fina A.J. Zamora M. Grino M.D. Culler J.P. Moreau A. Enjalbert L.H. Ouafik Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes J. Clin. Endocrinol. Metab. 85 2000 781 792
37. P. Jaquet G. Gunz A. Saveanu H. Dufour J. Taylor J. Dong S. Kim J.P. Moreau A. Enjalbert M.D. Culler Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy Eur. J. Endocrinol. 153 2005 135 141
38. P. Jaquet G. Gunz A. Saveanu A. Barlier H. Dufour J. Taylor J. Dong S. Kim J.P. Moreau M.D. Culler BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide J. Endocrinol. Invest. 28 2005 21 27
39. T. Kenakin Efficacy at G-protein-coupled receptors Nat. Rev. Drug Discov. 1 2002 103 110
40. T. Kenakin O. Onaran The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol. Sci. 23 2002 275 280
41. S.W. Lamberts P. Uitterlinden J.M. Klijn The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease Acta Endocrinol. (Copenh) 120 1989 760 766
42. A. Mansour J.H. Meador-Woodruff J.R. Bunzow O. Civelli H. Akil S.J. Watson Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and pituitary: an in situ hybridization-receptor autoradiographic analysis J. Neurosci. 10 1990 2587 2600
43. P. Marbach U. Briner M. Lemaire A. Schweitzer T. Terasaki From somatostatin to sandostatin: pharmacodynamics and pharmacokinetics Digestion 54 Suppl. 1 1993 9 13
44. C. Matrone R. Pivonello A. Colao P. Cappabianca L.M. Cavallo M.L. Del Basso De Caro J.E. Taylor M.D. Culler G. Lombardi G.F. Di Renzo L. Annunziato Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs Neuroendocrinology 79 2004 142 148
45. S. Maudsley B. Martin L.M. Luttrell The origins of diversity and specificity in g protein-coupled receptor signaling J. Pharmacol. Exp. Ther. 314 2005 485 494
46. D.W. McGraw K.A. Mihlbachler M.R. Schwarb F.F. Rahman K.M. Small K.F. Almoosa S.B. Liggett Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex J. Clin. Invest. 116 2006 1400 1409
47. G.M. Miller J.M. Alexander H.A. Bikkal L. Katznelson N.T. Zervas A. Klibanski Somatostatin receptor subtype gene expression in pituitary adenomas J. Clin. Endocrinol. Metab. 80 1995 1386 1392
48. M.E. Molitch Pharmacologic resistance in prolactinoma patients Pituitary 8 2005 43 52
49. L.N. Moller C.E. Stidsen B. Hartmann J.J. Holst Somatostatin receptors Biochim. Biophys. Acta 1616 2003 1 84
50. H. Murabe A. Shimatsu C. Ihara H. Mizuta Y. Nakamura I. Nagata H. Kikuchi K. Nakao Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction J. Neuroendocrinol. 8 1996 605 610
51. G.Y. Ng B.F. O’Dowd S.P. Lee H.T. Chung M.R. Brann P. Seeman S.R. George Dopamine D2 receptor dimers and receptor-blocking peptides Biochem. Biophys. Res. Commun. 227 1996 200 204
52. S. Nielsen S. Mellemkjaer L.M. Rasmussen T. Ledet J. Astrup J. Weeke J.O. Jorgensen Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas J. Clin. Endocrinol. Metab. 83 1998 2997 3000
53. R.S. Ostrom S.R. Post P.A. Insel Stoichiometry and compartmentation in G protein-coupled receptor signaling: implications for therapeutic interventions involving G(s) J. Pharmacol. Exp. Ther. 294 2000 407 412
54. D. O’Toole A. Saveanu A. Couvelard G. Gunz A. Enjalbert P. Jaquet P. Ruszniewski A. Barlier The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies Eur. J. Endocrinol. 155 2006 849 857
55. R. Panetta Y.C. Patel Expression of mRNA for all five human somatostatin receptors (hSSTR1–5) in pituitary tumors Life Sci. 56 1995 333 342
56. R.C. Patel U. Kumar D.C. Lamb J.S. Eid M. Rocheville M. Grant A. Rani T. Hazlett S.C. Patel E. Gratton Y.C. Patel Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells Proc. Natl. Acad. Sci. U.S.A. 99 2002 3294 3299
57. I. Pellegrini R. Rasolonjanahary G. Gunz P. Bertrand S. Delivet C.P. Jedynak C. Kordon F. Peillon P. Jaquet A. Enjalbert Resistance to bromocriptine in prolactinomas J. Clin. Endocrinol. Metab. 69 1989 500 509
58. M. Pfeiffer T. Koch H. Schroder M. Klutzny S. Kirscht H.J. Kreienkamp V. Hollt S. Schulz Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A) J. Biol. Chem. 276 2001 14027 14036
59. M. Pfeiffer T. Koch H. Schroder M. Laugsch V. Hollt S. Schulz Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization J. Biol. Chem. 277 2002 19762 19772
60. R. Pivonello C. Matrone M. Filippella L.M. Cavallo C. Di Somma P. Cappabianca A. Colao L. Annunziato G. Lombardi Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment J. Clin. Endocrinol. Metab. 89 2004 1674 1683
61. R. Pivonello D. Ferone W.W. de Herder J.M. Kros M.L. De Caro M. Arvigo L. Annunziato G. Lombardi A. Colao L.J. Hofland S.W. Lamberts Dopamine receptor expression and function in corticotroph pituitary tumors J. Clin. Endocrinol. Metab. 89 2004 2452 2462
62. S.G. Ren S. Kim J. Taylor J. Dong J.P. Moreau M.D. Culler S. Melmed Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand J. Clin. Endocrinol. Metab. 88 2003 5414 5421
63. E. Resmini P. Dadati J.L. Ravetti G. Zona R. Spaziante A. Saveanu P. Jaquet M.D. Culler F. Bianchi A. Rebora F. Minuto D. Ferone Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient J. Clin. Endocrinol. Metab. 92 2007 1592 1599
64. J.C. Reubi B. Waser J.C. Schaer J.A. Laissue Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands Eur. J. Nucl. Med. 28 2001 836 846
65. J.C. Reubi K.P. Eisenwiener H. Rink B. Waser H.R. Macke A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors Eur. J. Pharmacol. 456 2002 45 49
66. M. Rocheville D.C. Lange U. Kumar S.C. Patel R.C. Patel Y.C. Patel Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity Science 288 2000 154 157
67. M. Rocheville D.C. Lange U. Kumar R. Sasi R.C. Patel Y.C. Patel Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers J. Biol. Chem. 275 2000 7862 7869
68. A. Saveanu I. Morange-Ramos G. Gunz H. Dufour A. Enjalbert P. Jaquet A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies Eur. J. Endocrinol. 145 2001 35 41
69. A. Saveanu G. Gunz H. Dufour P. Caron F. Fina L. Ouafik M.D. Culler J.P. Moreau A. Enjalbert P. Jaquet Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas J. Clin. Endocrinol. Metab. 86 2001 140 145
70. A. Saveanu E. Lavaque G. Gunz A. Barlier S. Kim J.E. Taylor M.D. Culler A. Enjalbert P. Jaquet Demonstration of enhanced potency of a chimeric somatostatin–dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells J. Clin. Endocrinol. Metab. 87 2002 5545 5552
71. A. Saveanu G. Gunz S. Guillen H. Dufour M.D. Culler P. Jaquet Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas Neuroendocrinology 83 2006 258 263
72. J.C. Schaer B. Waser G. Mengod J.C. Reubi Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography Int. J. Cancer 70 1997 530 537
73. N. Sharif L. Gendron J. Wowchuk P. Sarret J. Mazella A. Beaudet T. Stroh Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2 Endocrinology 148 2007 2095 2105
74. I. Shimon X. Yan J.E. Taylor M.H. Weiss M.D. Culler S. Melmed Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors J. Clin. Invest. 100 1997 2386 2392
75. I. Shimon T. Rubinek M. Hadani N. Alhadef PTR-3173 (somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2,4 and 5 is a potent inhibitor of human GH secretion J. Endocrinol. Invest. 27 2004 721 727
76. H.V. Socin P. Chanson B. Delemer A. Tabarin V. Rohmer J. Mockel A. Stevenaert A. Beckers The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients Eur. J. Endocrinol. 148 2003 433 442
77. G.K. Stalla S.J. Brockmeier U. Renner C. Newton M. Buchfelder J. Stalla O.A. Muller Octreotide exerts different effects in vivo and in vitro in Cushing's disease Eur. J. Endocrinol. 130 1994 125 131
78. L. Stefaneanu K. Kovacs E. Horvath M. Buchfelder R. Fahlbusch L. Lancranjan Dopamine D2 receptor gene expression in human adenohypophysial adenomas Endocrine 14 2001 329 336
79. G.F. Taboada R.M. Luque W. Bastos R.F. Guimaraes J.B. Marcondes L.M. Chimelli R. Fontes P.J. Mata P.N. Filho D.P. Carvalho R.D. Kineman M.R. Gadelha Quantitative analysis of somatostatin receptor subtype (SSTR1–5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas Eur. J. Endocrinol. 156 2007 65 74
80. S. Terrillon M. Bouvier Roles of G-protein-coupled receptor dimerization EMBO Rep. 5 2004 30 34
81. E. Thodou G. Kontogeorgos D. Theodossiou M. Pateraki Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas J. Clin. Pathol. 59 2006 274 279
82. V.S. Thoss J. Perez A. Probst D. Hoyer Expression of five somatostatin receptor mRNAs in the human brain and pituitary Naunyn Schmiedebergs Arch. Pharmacol. 354 1996 411 419
83. J. van der Hoek W.W. de Herder R.A. Feelders A.J. van der Lely P. Uitterlinden V. Boerlin C. Bruns K.W. Poon I. Lewis G. Weckbecker T. Krahnke L.J. Hofland S.W. Lamberts A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients J. Clin. Endocrinol. Metab. 89 2004 638 645
84. J. van der Hoek M. Waaijers P.M. van Koetsveld D. Sprij-Mooij R.A. Feelders H.A. Schmid P. Schoeffter D. Hoyer D. Cervia J.E. Taylor M.D. Culler S.W. Lamberts L.J. Hofland Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells Am. J. Physiol. Endocrinol. Metab. 289 2005 E278 E287
85. H.L. Watt U. Kumar Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells Cancer Cell Int. 6 2006 5
86. G. Weckbecker U. Briner I. Lewis C. Bruns SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs Endocrinology 143 2002 4123 4130
87. A. Yoshihara O. Isozaki N. Hizuka Y. Nozoe C. Harada M. Ono T. Kawamata O. Kubo T. Hori K. Takano Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy Endocr. J. 54 2007 133 138
88. M.C. Zatelli D. Piccin F. Tagliati M.R. Ambrosio A. Margutti R. Padovani M. Scanarini M.D. Culler E.C. degli Uberti Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion J. Clin. Endocrinol. Metab. 88 2003 2797 2802
89. M.C. Zatelli D. Piccin A. Bottoni M.R. Ambrosio A. Margutti R. Padovani M. Scanarini J.E. Taylor M.D. Culler L. Cavazzini E.C. degli Uberti Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro J. Clin. Endocrinol. Metab. 89 2004 5181 5188
90. M.C. Zatelli D. Piccin F. Tagliati A. Bottoni M.R. Ambrosio A. Margutti M. Scanarini M. Bondanelli M.D. Culler E.C. degli Uberti Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro J. Mol. Endocrinol. 35 2005 333 341